BI 1744 CL (olodaterol) IV infusion in healthy males

Phase 1, randomised, single-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with abnormal findings in physical examination at Day 10 and Number of patients with clinically significant changes in vital signs at Day 10. Started Oct 2006; status: terminated.